Abstract
Abstract We herein report a case of HCC who got CR treated with lenvatinib. A 70-year old man had chronic hepatitis C and got a virologic response by PegIFN+Riv in 201X-4. He drunk liquor 5 go a day. He underwent hepatic left lobe resection for the Hepatocellular carcinoma, moderately differentiated, vp2, vv0,va0, b3, single-engine, 3.2cm, the Background liver A1/F2, as a diagnosis of stageIII for HCC in Dec 201X-1. In April 201X, CT and MRI showed recurrent HCC occupied great part of the residual liver (portal vein embolus vp3 (P7)). Blood test results showed elevation of AST 70U/l, ALT 90U/l, G-GTP 255U/l, T-Bil 0.9mg/dl, AFP 245ng/ml, PIVKA-II 843mAU/ml. His performance status (PS) was 0, and, he received lemvatinib monotherapy (8mg/day) in May. Early adverse events were hoarse voice, hand-foot syndrome and hypertension, all Grade 1. He used anti-hypertensive agent, steroid cream. In Oct, Anorexia appeared, so lenvatinib were reduced to 4mg so that anorexia improved, his BP normalized without agent and his hoarse voice disappeared. Tumor marker became normalized in Sep. CT scan showed good PR in Jun, Aug, and Oct gradually. In Dec CT scan showed elimination of early enhancement of HCC, although remaining P7 stenosis. We diagnosed CR and that is now continuing in 201X+1. We experienced a rare case of rapid HCC growth obtained CR treated with lenvatinib.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.